ClinicalTrials.gg
CompletedNCT01203644Updated Jan 25, 2021Results posted

Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair

A Phase 2 interventional study of SKY0402 and Bupivacaine HCl in Inguinal Hernia, sponsored by Pacira Pharmaceuticals, Inc. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing bupivacaine in Hernia, Inguinal — 1 open to participants now, 2 under way, none of them phase 3. Bupivacaine · Hernia, Inguinal.

Enrollment
9th of 19
76 · median 70
Started
2004
the only one that year
Phase 2
3 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies testing bupivacaine in Hernia, Inguinal, this one is the 9th largest by enrollment, is the only one that started in 2004, is one of 3 in phase 2, and was the 1st registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

1 of the 19 studies testing bupivacaine in Hernia, Inguinal is open now. Recruiting first, the newest first:

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing bupivacaine in Hernia, Inguinal, or all of them as a file.
02

Study summary

The primary objective of this study was to determine the appropriate dose of SKY0402 for the management of postoperative pain following inguinal hernia repair. This study evaluated the safety, efficacy, and pharmacokinetics of SKY0402 compared with a 100 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects undergoing inguinal hernia repair. Study drug was administered by surgical wound infiltration at the end of the hernia repair procedure.

Read the detailed description

SKY0402 was administered in a dose escalating/de-escalating fashion, with a low starting dose in Cohort 1 that was to be increased or decreased in subsequent cohorts based on safety and analgesic effects. The decision to proceed to the next cohort (i.e., increase or decrease the dose) was made by a Cohort Data Review Committee following a review of the data from the previous cohort. Subjects were randomized to receive either SKY0402 or bupivacaine HCl at a ratio of 1:1 in Cohort 1 and at a ratio of 3:1 in subsequent cohorts. The dose of bupivacaine HCl (100 mg) remained constant for all cohorts.

03

Conditions studied

  • Inguinal Hernia

Keywords

  • Postoperative pain
  • Analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males ≥18 years of age at the Screening visit.
  2. Scheduled to undergo unilateral inguinal hernia repair under general anesthesia, using an open, tension free procedure (e.g., Lichtenstein technique with or without mesh).
  3. American Society of Anesthesiology (ASA) Physical Class 1 or 2.
  4. Able and willing to comply with all study visits and procedures.
  5. Capable of speaking and understanding the local language sufficiently to provide responses to pain assessment scales.
  6. Willing and capable of providing written .

Exclusion criteria

Exclusion Criteria:

  1. abnormalities at Screening or on Day 1 (pre administration).
  2. Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.
  3. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, might have increased the risk of surgery or complicated the subject's postoperative course.
  4. Opioid medication usage during the 7 day period preceding the administration of study drug.
  5. Current medical conditions that could have required treatment with analgesic medications in the postoperative period for pain that was not surgically related (e.g., rheumatoid arthritis).
  6. >30 kg/m\^2
  7. Body weight \<60 kg.
  8. History of or idiosyncratic reaction to amide type local anesthetic agents.
  9. History of hypersensitivity, idiosyncratic reactions, and other to the pain control agents (opioid or non-opioid) anticipated to be used postoperatively. These contraindications may have included: angioedema and bronchospastic reactivity to non steroidal anti inflammatory drug, peptic ulcer (active within the last three months), hepatic or renal insufficiency.
  10. Coagulation disorders or ongoing anticoagulation treatment.
  11. Administration of an drug within 30 days or five half lives (of elimination), whichever was longer, prior to study drug administration.
  12. Suspected or known history of substance abuse and/or alcoholism.
  13. Clinically significant complications during the hernia repair surgery (e.g., excessive bleeding), which might have rendered the subject medically unstable or might have complicated the subject's postoperative course.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Active comparator
    Bupivacaine HCl

    (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402

    Drug: SKY0402

  • Active comparator
    SKY0402

    Low dose, low-mid dose, mid-dose, and high dose

    Drug: Bupivacaine HCl

Interventions

  • Single dose of SKY0402 administered locally into the surgical wound.

  • Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.

06

What researchers measure

Primary outcomes

  1. Time to First Use of Supplemental Pain Medication

    The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain

    Time frame: Through 96 hours postdose

Secondary outcomes

  1. Adverse Events

    Safety assessments included monitoring of treatment-emergent adverse events

    Time frame: Through 30 days postdose

07

Results

Posted May 14, 2012

Participant flow

Participant flow — Overall Study
MilestoneBupivacaine HClSKY0402
Started2650
Completed2650
Not completed00

Outcome measures

PrimaryTime to First Use of Supplemental Pain Medication

The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain

Time frame:
Through 96 hours postdose
Reported as:
Median · hours
Time to First Use of Supplemental Pain Medication
hoursBupivacaine HClSKY0402 Low DoseSKY0402 Low-mid DoseSKY0402 High-mid DoseSKY0402 High Dose
Time to First Use of Supplemental Pain Medication4.2 (1.3 to 13.7)13.75 (2.1 to 62.7)3.9 (0.8 to 7.4)5.2 (1.9 to 18.8)5.5 (1.4 to 96)
SecondaryAdverse Events

Safety assessments included monitoring of treatment-emergent adverse events

Time frame:
Through 30 days postdose

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivacaine HCl—0/26 (0%)10/26 (38.5%)
SKY0402—2/50 (4%)12/50 (24%)
Most frequent serious events
Most frequent serious events
EventBupivacaine HClSKY0402
Postoperative hematomaInjury, poisoning and procedural complications0/261/50
Urinary Retention/BPHRenal and urinary disorders0/261/50
Most frequent other events
Most frequent other events
EventBupivacaine HClSKY0402
NauseaGastrointestinal disorders2/264/50
Localized oedemaGeneral disorders2/261/50
Wound infectionInfections and infestations2/260/50
Urinary retentionRenal and urinary disorders2/261/50
PyrexiaGeneral disorders1/263/50
Hypertension NOSVascular disorders1/263/50

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bupivacaine HClSKY0402Total
<=18 years000
Between 18 and 65 years243660
>=65 years21416
Age, Continuous
Age, Continuous(years)Bupivacaine HClSKY0402Total
Mean51.3 ± 12.655.1 ± 1653.8 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Bupivacaine HClSKY0402Total
Female000
Male265076
Region of Enrollment
Region of Enrollment(participants)Bupivacaine HClSKY0402Total
Belgium088
Australia162642
United Kingdom41216
Netherlands6410
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jan 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 6 years 4 months after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2010
First posted
Sep 16, 2010
Start
Dec 2004
Primary completionActual
Jan 2006
CompletionActual
Dec 2006
Results delay requested
Sep 22, 2010
Results first posted
May 14, 2012
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01203644
Responsible party
Sponsor
First posted
Sep 16, 2010
Start date
Dec 2004
Primary completion
Jan 2006
Completion
Dec 2006
Results posted
May 14, 2012
Last update
Jan 25, 2021

Study contacts

Kay Warnott, RN, ACNP
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion